© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
Surrogate End Point for Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy
Affiliations of authors: A. V. D’Amico, Department of Radiation Oncology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA; J. W. Moul, L. Sun, Department of Surgery and Urology Service, Center for Prostate Disease Research, Uniformed Services University and Walter Reed Army Medical Center, Bethesda, MD; P. R. Carroll, D. Lubeck, Department of Urology, University of California, San Francisco; M.-H. Chen, Department of Statistics, University of Connecticut, Storrs.
Correspondence to: Anthony V. D’Amico, MD, PhD, Brigham and Women’s Hospital, Department of Radiation Oncology, 75 Francis St., L-2 Level, Boston, MA 02215 (e-mail: adamico{at}lroc.harvard.edu).
Background: The relationship between prostate-specific antigen (PSA)–defined recurrence and prostate cancer–specific mortality remains unclear. Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is a surrogate end point for prostate cancer–specific mortality by analyzing two multi-institutional databases. Methods: Baseline, treatment, and follow-up information was compiled on a cohort of 8669 patients with prostate cancer treated with surgery (5918 men) or radiation (2751 men) from January 1, 1988, through January 1, 2002, for localized or locally advanced, non-metastatic prostate cancer. We used a Cox regression analysis to test whether the post-treatment PSA-DT was a prognostic factor that was independent of treatment received. All statistical tests were two-sided. Results: The post-treatment PSA-DT was statistically significantly associated with time to prostate cancer–specific mortality and with time to all-cause mortality (all PCox<.001). However, the treatment received was not statistically significantly associated with time to prostate cancer–specific mortality after PSA-defined disease recurrence for patients with a PSA-DT of less than 3 months (PCox = .90) and for patients with a PSA-DT of 3 months or more (PCox = .28) when controlling for the specific value of the PSA-DT. Furthermore, after a PSA-defined recurrence, a PSA-DT of less than 3 months was statistically significantly associated with time to prostate cancer–specific mortality (median time = 6 years; hazard ratio = 19.6, 95% confidence interval = 12.5 to 30.9). Conclusion: A post-treatment PSA-DT of less than 3 months and the specific value of the post-treatment PSA-DT when it is 3 months or more appear to be surrogate end points for prostate cancer–specific mortality after surgery or radiation therapy. We recommend that consideration be given to initiating androgen suppression therapy at the time of a PSA-defined recurrence when the PSA-DT is less than 3 months to delay the imminent onset of metastatic bone disease.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Surrogate End Points for Prostate Cancer: What Is Prostate-Specific Antigen Telling Us?
- Howard M. Sandler and Michelle L. DeSilvio
J Natl Cancer Inst 2003 95: 1352-1353.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  M. F. O'Brien, A. M. Cronin, P. A. Fearn, B. Smith, J. Stasi, B. Guillonneau, P. T. Scardino, J. A. Eastham, A. J. Vickers, and H. Lilja Pretreatment Prostate-Specific Antigen (PSA) Velocity and Doubling Time Are Associated With Outcome but Neither Improves Prediction of Outcome Beyond Pretreatment PSA Alone in Patients Treated With Radical Prostatectomy J. Clin. Oncol., August 1, 2009; 27(22): 3591 - 3597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Stark, S. Perner, M. J. Stampfer, J. A. Sinnott, S. Finn, A. S. Eisenstein, J. Ma, M. Fiorentino, T. Kurth, M. Loda, et al. Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3? J. Clin. Oncol., July 20, 2009; 27(21): 3459 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, P. Choyke, D. S. Coffey, and for The Prostate Cancer Imaging Working Group Challenges in Clinical Prostate Cancer: Role of Imaging Am. J. Roentgenol., June 1, 2009; 192(6): 1455 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Dale, J. Hemmerich, K. Bylow, S. Mohile, M. Mullaney, and W. M. Stadler Patient Anxiety About Prostate Cancer Independently Predicts Early Initiation of Androgen Deprivation Therapy for Biochemical Cancer Recurrence in Older Men: A Prospective Cohort Study J. Clin. Oncol., April 1, 2009; 27(10): 1557 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Stein, J. Yang, S. E. Bates, and T. Fojo Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage Oncologist, October 1, 2008; 13(10): 1055 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. Stein, W. D. Figg, W. Dahut, A. D. Stein, M. B. Hoshen, D. Price, S. E. Bates, and T. Fojo Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data Oncologist, October 1, 2008; 13(10): 1046 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Saxe, J. M. Major, L. Westerberg, S. Khandrika, and T. M. Downs Biological Mediators of Effect of Diet and Stress Reduction on Prostate Cancer Integr Cancer Ther, September 1, 2008; 7(3): 130 - 138. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Madan, J. L. Gulley, J. Schlom, S. M. Steinberg, D. J. Liewehr, W. L. Dahut, and P. M. Arlen Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy Clin. Cancer Res., July 15, 2008; 14(14): 4526 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, M.-H. Chen, A. A. Renshaw, B. Loffredo, and P. W. Kantoff Risk of Prostate Cancer Recurrence in Men Treated With Radiation Alone or in Conjunction With Combined or Less Than Combined Androgen Suppression Therapy J. Clin. Oncol., June 20, 2008; 26(18): 2979 - 2983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nabhan Is Chemotherapy the Standard for Asymptomatic Androgen-Independent Prostate Cancer? J. Clin. Oncol., May 10, 2008; 26(14): 2413 - 2414. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oudard, E. Banu, F. Scotte, A. Banu, J. Medioni, P. Beuzeboc, F. Joly, J.-M. Ferrero, F. Goldwasser, and J.-M. Andrieu Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients Ann. Onc., November 1, 2007; 18(11): 1828 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, F. J. Dorey, P. C. Walsh, and A. W. Partin Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality J. Clin. Oncol., May 1, 2007; 25(13): 1765 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Tollefson, J. M. Slezak, B. C. Leibovich, H. Zincke, and M. L. Blute Stratification of Patient Risk Based on Prostate-Specific Antigen Doubling Time After Radical Retropubic Prostatectomy Mayo Clin. Proc., April 1, 2007; 82(4): 422 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mehra, M. Penning, J. Maas, N. van Daal, R. H. Giles, and E. E. Voest Circulating Mitochondrial Nucleic Acids Have Prognostic Value for Survival in Patients with Advanced Prostate Cancer Clin. Cancer Res., January 15, 2007; 13(2): 421 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Pisansky External-beam radiotherapy for localized prostate cancer. N. Engl. J. Med., October 12, 2006; 355(15): 1583 - 1591. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Henshall, L. G. Horvath, D. I. Quinn, S. A. Eggleton, J. J. Grygiel, P. D. Stricker, A. V. Biankin, J. G. Kench, and R. L. Sutherland Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst, October 4, 2006; 98(19): 1420 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Saxe, J. M. Major, J. Y. Nguyen, K. M. Freeman, T. M. Downs, and C. E. Salem Potential Attenuation of Disease Progression in Recurrent Prostate Cancer With Plant-Based Diet and Stress Reduction Integr Cancer Ther, September 1, 2006; 5(3): 206 - 213. [Abstract] [PDF]
|
|
|
|
|
|
J. Y. Nguyen, J. M. Major, C. J. Knott, K. M. Freeman, T. M. Downs, and G. A. Saxe Adoption of a Plant-Based Diet by Patients with Recurrent Prostate Cancer Integr Cancer Ther, September 1, 2006; 5(3): 214 - 223. [Abstract] [PDF]
|
|
|
|
|
|
A. V. D'Amico, M. Loffredo, A. A. Renshaw, B. Loffredo, and M.-H. Chen Six-Month Androgen Suppression Plus Radiation Therapy Compared With Radiation Therapy Alone for Men With Prostate Cancer and a Rapidly Increasing Pretreatment Prostate-Specific Antigen Level J. Clin. Oncol., September 1, 2006; 24(25): 4190 - 4195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stephenson, M. W. Kattan, J. A. Eastham, Z. A. Dotan, F. J. Bianco Jr, H. Lilja, and P. T. Scardino Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition J. Clin. Oncol., August 20, 2006; 24(24): 3973 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Ferrari, N. N. Stone, R. Kurek, E. Mulligan, R. McGregor, R. Stock, P. Unger, U. Tunn, A. Kaisary, M. Droller, et al. Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment J. Clin. Oncol., July 1, 2006; 24(19): 3081 - 3088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Pantuck, J. T. Leppert, N. Zomorodian, W. Aronson, J. Hong, R. J. Barnard, N. Seeram, H. Liker, H. Wang, R. Elashoff, et al. Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer. Clin. Cancer Res., July 1, 2006; 12(13): 4018 - 4026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shimazaki, K. Akakura, H. Suzuki, T. Ichikawa, H. Tsuji, H. Ishikawa, M. Harada, and H. Tsujii Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Jpn. J. Clin. Oncol., May 1, 2006; 36(5): 290 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Carter Assessing risk: does this patient have prostate cancer? J Natl Cancer Inst, April 19, 2006; 98(8): 506 - 507. [Full Text] [PDF]
|
|
|
|
|
|
S. F. Slovin, A. S. Wilton, G. Heller, and H. I. Scher Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy Clin. Cancer Res., December 15, 2005; 11(24): 8669 - 8673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Cooperberg, J. W. Moul, and P. R. Carroll The Changing Face of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8146 - 8151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Hayes and A. Pollack Parameters for Treatment Decisions for Salvage Radiation Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8204 - 8211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Ryan and E. J. Small Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate J. Clin. Oncol., November 10, 2005; 23(32): 8225 - 8231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Webster, E. J. Small, B. I. Rini, and E. D. Kwon Prostate Cancer Immunology: Biology, Therapeutics, and Challenges J. Clin. Oncol., November 10, 2005; 23(32): 8262 - 8269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Freedland, W. B. Isaacs, E. A. Platz, M. K. Terris, W. J. Aronson, C. L. Amling, J. C. Presti Jr, and C. J. Kane Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search Database Study J. Clin. Oncol., October 20, 2005; 23(30): 7546 - 7554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhou, M.-H. Chen, D. McLeod, P. R. Carroll, J. W. Moul, and A. V. D'Amico Predictors of Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy J. Clin. Oncol., October 1, 2005; 23(28): 6992 - 6998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stephenson, P. T. Scardino, J. A. Eastham, F. J. Bianco Jr, Z. A. Dotan, C. J. DiBlasio, A. Reuther, E. A. Klein, and M. W. Kattan Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy J. Clin. Oncol., October 1, 2005; 23(28): 7005 - 7012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stewart, H. I. Scher, M.-H. Chen, D. G. McLeod, P. R. Carroll, J. W. Moul, and A. V. D'Amico Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen Failure J. Clin. Oncol., September 20, 2005; 23(27): 6556 - 6560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lukka, C. Hayter, J. A. Julian, P. Warde, W. J. Morris, M. Gospodarowicz, M. Levine, J. Sathya, R. Choo, H. Prichard, et al. Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6132 - 6138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Collette, T. Burzykowski, K. J. Carroll, D. Newling, T. Morris, and F. H. Schroder Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals J. Clin. Oncol., September 1, 2005; 23(25): 6139 - 6148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, M.-H. Chen, K. A. Roehl, and W. J. Catalona Identifying Patients at Risk for Significant Versus Clinically Insignificant Postoperative Prostate-Specific Antigen Failure J. Clin. Oncol., August 1, 2005; 23(22): 4975 - 4979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, F. J. Dorey, P. C. Walsh, and A. W. Partin Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy JAMA, July 27, 2005; 294(4): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, A. A. Renshaw, B. Sussman, and M.-H. Chen Pretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy JAMA, July 27, 2005; 294(4): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rubin, T. A. Bismar, O. Andren, L. Mucci, R. Kim, R. Shen, D. Ghosh, J. T. Wei, A. M. Chinnaiyan, H.-O. Adami, et al. Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1424 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Smith, F. Kabbinavar, F. Saad, A. Hussain, M. C. Gittelman, D. L. Bilhartz, C. Wynne, R. Murray, N. R. Zinner, C. Schulman, et al. Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer J. Clin. Oncol., May 1, 2005; 23(13): 2918 - 2925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Numata, K. Azuma, K. Hashine, and Y. Sumiyoshi Predictor of Response to Salvage Radiotherapy in Patients with PSA Recurrence after Radical Prostatectomy: the Usefulness of PSA Doubling Time Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 256 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Morris, T. Akhurst, S. M. Larson, M. Ditullio, E. Chu, K. Siedlecki, D. Verbel, G. Heller, W. K. Kelly, S. Slovin, et al. Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy Clin. Cancer Res., May 1, 2005; 11(9): 3210 - 3216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hussain, N. Dawson, P. Amin, C. Engstrom, B. Dorsey, E. Siegel, and C. Guo Docetaxel Followed by Hormone Therapy in Men Experiencing Increasing Prostate-Specific Antigen After Primary Local Treatments for Prostate Cancer J. Clin. Oncol., April 20, 2005; 23(12): 2789 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Freedland, W. B. Isaacs, L. A. Mangold, S. K. Yiu, K. A. Grubb, A. W. Partin, J. I. Epstein, P. C. Walsh, and E. A. Platz Stronger Association between Obesity and Biochemical Progression after Radical Prostatectomy among Men Treated in the Last 10 Years Clin. Cancer Res., April 15, 2005; 11(8): 2883 - 2888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M.G. Taylor, M. Yu, and H. M. Sandler Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer J. Clin. Oncol., February 1, 2005; 23(4): 816 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Zelefsky, L. Ben-Porat, H. I. Scher, H. M. Chan, P. A. Fearn, Z. Y. Fuks, S. A. Leibel, and E.S. Venkatraman Outcome Predictors for the Increasing PSA State After Definitive External-Beam Radiotherapy for Prostate Cancer J. Clin. Oncol., February 1, 2005; 23(4): 826 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, A. A. Renshaw, K. Cote, M. Hurwitz, C. Beard, M. Loffredo, and M.-H. Chen Impact of the Percentage of Positive Prostate Cores on Prostate Cancer-Specific Mortality for Patients With Low or Favorable Intermediate-Risk Disease J. Clin. Oncol., September 15, 2004; 22(18): 3726 - 3732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, J. Manola, M. Loffredo, A. A. Renshaw, A. DellaCroce, and P. W. Kantoff 6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial JAMA, August 18, 2004; 292(7): 821 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, M.-H. Chen, K. A. Roehl, and W. J. Catalona Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy N. Engl. J. Med., July 8, 2004; 351(2): 125 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eisenberger and A. Partin Progress toward Identifying Aggressive Prostate Cancer N. Engl. J. Med., July 8, 2004; 351(2): 180 - 181. [Full Text] [PDF]
|
|
|
|
|
|
H. L. Kaufman, W. Wang, J. Manola, R. S. DiPaola, Y.-J. Ko, C. Sweeney, T. L. Whiteside, J. Schlom, G. Wilding, and L. M. Weiner Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group J. Clin. Oncol., June 1, 2004; 22(11): 2122 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, D. S. Coffey, B. A. Chabner, A. P. Dicker, K. Z. Guyton, P. D. Nisen, H. R. Soule, and A. V. D'Amico Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3927 - 3933. [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, J. W. Moul, P. R. Carroll, K. Cote, L. Sun, D. Lubeck, A. A. Renshaw, M. Loffredo, and M.-H. Chen Intermediate End Point for Prostate Cancer-Specific Mortality Following Salvage Hormonal Therapy for Prostate-Specific Antigen Failure J Natl Cancer Inst, April 7, 2004; 96(7): 509 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Sandler and M. L. DeSilvio Surrogate End Points for Prostate Cancer: What Is Prostate-Specific Antigen Telling Us? J Natl Cancer Inst, September 17, 2003; 95(18): 1352 - 1353. [Full Text] [PDF]
|
|